Mr Mitchell Nussbaum > Loeb & Loeb LLP > New York, United States > Lawyer Profile

Loeb & Loeb LLP
345 PARK AVENUE
NEW YORK, NY 10154
NEW YORK
United States

Work Department

Capital Markets and Corporate

Position

Vice Chair, Loeb & Loeb LLP; Co-Chair, Capital Markets and Corporate

Career

For more information about Mitchell Nussbaum, please visit his official Loeb.com biography: Mitchell S. Nussbaum | Capital Markets Lawyer | Loeb & Loeb LLP

Education

Syracuse University College of Law, J.D., Member, Syracuse University Law Review
University of Rochester, B.A.

Lawyer Rankings

United States > Healthcare > Life sciences

Loeb & Loeb LLP combines expertise in FDA regulatory issues with a specialization in patent litigation, advising clients on the marketing and commercialization of their drugs and representing them in patent disputes, including those falling under Hatch-Waxman. Washington DC-based Jim Czaban takes the lead on FDA compliance across the life cycle of medical products and representing them in enforcement actions. Mitchell Nussbaum handles a range of corporate and capital markets matters, with Fran Stoller on research collaborations, licensing agreements and securities law. Mark Waddell represents clients in Hatch-Waxman and biosimilars litigation, as does Kathleen Gersh, who also advises on FDA regulation. Unless otherwise specified, all lawyers are New York-based.

United States > M&A/corporate and commercial > M&A: middle-market (sub-$500m)

(Hall of Fame)

Mitchell NussbaumLoeb & Loeb LLP